Calpain 2-dependent IκBα degradation mediates CPT-11 secondary resistance in colorectal cancer xenografts
- Nina Fenouille,
- Sebastien Grosso,
- Yunchao Su,
- Mary Didier,
- Rodolphe Pontier-Bres,
- Véronique Imbert
- University of Nice,
- Universite Cote d'Azur,
- Institut de Pharmacologie Moleculaire et Cellulaire,
- ,
- ,
Scholary Output:
Contribution to journal
Article
Research
Peer-reviewSustainable Development Goals
- SDG 3 Good Health and Well
Abstract
<p>CPT-11 (irinotecan), the first-line chemotherapy for advanced stage colorectal cancer, remains inactive in about half of patients (primary chemoresistance) and almost all initial responders develop secondary resistance after several courses of treatment (8 months on average). Nude mice bearing HT-29 colon cancer xenografts were treated with CPT-11 and/or an NF-κB inhibitor for two courses. We confirm that NF-κB inhibition potentiated CPT-11 anti-tumoural effect after the first course of treatment. However, tumours grew again at the end of the second course of treatment, generating resistant tumours. We observed an increase in the basal NF-κB activation in resistant tumours and in two resistant sublines, either obtained from resistant HT-29 tumours (HT-29R cells) or generated in vitro (RSN cells). The decrease of NF-κB activation in HT-29R and RSN cells by stable transfections with the super-repressor form of IκBα augmented their sensitivity to CPT-11. Comparing gene expression profiles of HT-29 and HT-29R cells, we identified the S100A10/Annexin A2 complex and calpain 2 as over-expressed potential NF-κB inducers. SiRNA silencing of calpain 2 but not of S100A10 and/or annexin A2, resulted in a decrease in NF-κB activation, an increase in cellular levels of IκBα and a partial restoration of the CPT-11 sensitivity in both HT-29R and RSN cells, suggesting that calpain 2-dependent IκBα degradation mediates CPT-11 secondary resistance. Thus, targeted therapies directed against calpain 2 may represent a novel strategy to enhance the anti-cancer efficacy of CPT-11.</p>
Publication Information
Output type
Scholary Output:
Contribution to journal
Article
Research
Peer-reviewOriginal language
English (US)Pages from-to (Number of pages)
Pages 118-129 (12 pages)Journal (Volume, Issue Number)
Journal of Pathology (Volume 227, Issue 1)Publication milestones
- Published - 05/2012
Publication status
Published - 05/2012
ISSN
0022-3417Publication IDs
- Scopus: 84859631303
- PubMed: 22069124
Publication metrics
Metrics
Fractional count
1
Fractional count
0.10
Fractional count
9
Fractional count
0.90
Fractional count
1
Fractional count
1
SciVal
FWCI
1.26
SciVal
Author count
10
SciVal
citations
20
SciVal
Paper percentile
78
PlumX, opens in new tab
Captures
21
Citation count
27
